X4 Pharmaceuticals (XFOR) Expected to Announce Quarterly Earnings on Tuesday

X4 Pharmaceuticals (NASDAQ:XFOR) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.17) per share and revenue of $1.07 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

X4 Pharmaceuticals Trading Down 7.8 %

XFOR stock opened at $0.31 on Tuesday. The company has a market cap of $53.50 million, a price-to-earnings ratio of -3.49 and a beta of 0.39. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The business has a fifty day simple moving average of $0.48 and a 200-day simple moving average of $0.54. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 74,773 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. The trade was a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 202,663 shares of company stock valued at $91,198. Company insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

A hedge fund recently raised its stake in X4 Pharmaceuticals stock. Bank of America Corp DE boosted its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 133,502 shares of the company’s stock after acquiring an additional 22,485 shares during the period. Bank of America Corp DE owned about 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent quarter. 72.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $1.50 price objective on shares of X4 Pharmaceuticals in a report on Friday, February 7th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.